Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy

Detalles Bibliográficos
Autores principales: Zhao, Guo, Wang, Shuhang, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213180/
https://www.ncbi.nlm.nih.gov/pubmed/37250972
http://dx.doi.org/10.1016/j.omto.2023.05.001
_version_ 1785047561026928640
author Zhao, Guo
Wang, Shuhang
Li, Ning
author_facet Zhao, Guo
Wang, Shuhang
Li, Ning
author_sort Zhao, Guo
collection PubMed
description
format Online
Article
Text
id pubmed-10213180
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-102131802023-05-27 Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy Zhao, Guo Wang, Shuhang Li, Ning Mol Ther Oncolytics Commentary American Society of Gene & Cell Therapy 2023-05-20 /pmc/articles/PMC10213180/ /pubmed/37250972 http://dx.doi.org/10.1016/j.omto.2023.05.001 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Commentary
Zhao, Guo
Wang, Shuhang
Li, Ning
Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
title Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
title_full Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
title_fullStr Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
title_full_unstemmed Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
title_short Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
title_sort adenovirotherapy delivering cross-hybrid igga fc engineering pd-l1 inhibitors for enhanced cancer immunotherapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213180/
https://www.ncbi.nlm.nih.gov/pubmed/37250972
http://dx.doi.org/10.1016/j.omto.2023.05.001
work_keys_str_mv AT zhaoguo adenovirotherapydeliveringcrosshybridiggafcengineeringpdl1inhibitorsforenhancedcancerimmunotherapy
AT wangshuhang adenovirotherapydeliveringcrosshybridiggafcengineeringpdl1inhibitorsforenhancedcancerimmunotherapy
AT lining adenovirotherapydeliveringcrosshybridiggafcengineeringpdl1inhibitorsforenhancedcancerimmunotherapy

Ejemplares similares